AR127948A1 - Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica - Google Patents
Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónicaInfo
- Publication number
- AR127948A1 AR127948A1 ARP220103413A ARP220103413A AR127948A1 AR 127948 A1 AR127948 A1 AR 127948A1 AR P220103413 A ARP220103413 A AR P220103413A AR P220103413 A ARP220103413 A AR P220103413A AR 127948 A1 AR127948 A1 AR 127948A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- 3alkyl
- heterocyclyl
- kidney disease
- chronic kidney
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000038000 non-diabetic chronic kidney disease Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para tratar la enfermedad renal crónica (CKD) diabética y no diabética, caracterizado porque el método comprende administrar a un paciente que lo necesite una cantidad farmacéuticamente eficaz de un compuesto de la fórmula (1) o una sal aceptable desde el punto de vista farmacéutico de este, en donde: Cy es un sistema de anillo monocíclico o bicíclico seleccionado de C₃₋₁₀cicloalquilo, heterociclilo, arilo y heteroarilo, en donde cada uno de dichos grupos C₃₋₁₀cicloalquilo, heterociclilo, arilo y heteroarilo está opcional e independientemente sustituido con uno, dos o tres grupos sustituyentes seleccionados de halógeno, -C₁₋₃-alquilo, -OC₁₋₃-alquilo, -CF₃, ciano, oxo, -N(C₁₋₃-alquilo)₂, -NH(C₁₋₃-alquilo), -NHCOC₁₋₃-alquilo, -C(O)C₁₋₃-alquilo, -C(O)OC₁₋₃alquilo, hidroxiC₁₋₃alquilo o heteroarilo; y R¹ y R² se seleccionan independientemente de H, C₁₋₃alquilo, hidroxiC₁₋₃alquilo, -CH₂NHC(O)OC₁₋₄alquilo, -CH₂OC(O)C₁₋₄alquilo, -C(O)OC₁₋₄-alquilo, -C(O)H, -COOH, -C(O)NHC₁₋₄-alquilo y C(O)N(C₁₋₄-alquilo)₂; o R¹ y R² tomados en conjunto forman un C₃₋₆cicloalquilo o C₃₋₆-heterociclilo. Reivindicación 12: El método de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque comprende además administrar al paciente una cantidad farmacéuticamente eficaz de un inhibidor de SGLT2, o una sal aceptable desde el punto de vista farmacéutico de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289177P | 2021-12-14 | 2021-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127948A1 true AR127948A1 (es) | 2024-03-13 |
Family
ID=85151059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103413A AR127948A1 (es) | 2021-12-14 | 2022-12-13 | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12263157B2 (es) |
| EP (1) | EP4447961A1 (es) |
| JP (1) | JP2025500826A (es) |
| KR (1) | KR20240122521A (es) |
| CN (1) | CN118401241A (es) |
| AR (1) | AR127948A1 (es) |
| AU (1) | AU2022415313A1 (es) |
| CA (1) | CA3236890A1 (es) |
| CL (1) | CL2024001470A1 (es) |
| MX (1) | MX2024007335A (es) |
| TW (1) | TW202339719A (es) |
| WO (1) | WO2023114170A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202510887A (zh) * | 2023-07-17 | 2025-03-16 | 美商礦物質醫療股份有限公司 | 以勞倫卓司他(lorundrostat)或勞倫卓司他與sglt2抑制劑之組合治療慢性腎臟病(ckd)或ckd與高血壓之方法 |
| WO2025125513A1 (en) * | 2023-12-15 | 2025-06-19 | AstraZeneca Ireland Limited | Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension |
| US20250255851A1 (en) * | 2024-02-14 | 2025-08-14 | Boehringer Ingelheim International Gmbh | Solid forms of an aldosterone synthase inhibitor |
| WO2025190858A1 (en) * | 2024-03-12 | 2025-09-18 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitor for treating heart failure |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU669226B2 (en) | 1992-10-20 | 1996-05-30 | Fumie Sato | Prostaglandine derivative |
| AU714033B2 (en) | 1996-07-19 | 1999-12-16 | Nissan Chemical Industries Ltd. | Method for producing purified epoxy compound |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| UA88925C2 (en) | 2002-10-15 | 2009-12-10 | Оцука Фармасьютикал Ко., Лтд. | 4-nitroimidazole derivatives |
| ES2526892T3 (es) | 2002-10-15 | 2015-01-16 | Otsuka Pharmaceutical Co., Ltd. | Método para preparar un compuesto 2-halo-4-nitroimidazol |
| CA2644578A1 (en) | 2006-03-03 | 2007-09-07 | Torrent Pharmaceuticals Ltd | Novel dual action receptors antagonists (dara) at the ati and eta receptors |
| CN101410389A (zh) | 2006-03-29 | 2009-04-15 | 诺瓦提斯公司 | 有机化合物 |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| JP2007297305A (ja) | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| CN101506216A (zh) | 2006-08-25 | 2009-08-12 | 诺瓦提斯公司 | 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物 |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| KR20110042342A (ko) | 2008-08-05 | 2011-04-26 | 다우 글로벌 테크놀로지스 엘엘씨 | 고체 에폭시 수지의 제조 |
| EP2341052A4 (en) | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
| AR073629A1 (es) | 2008-10-07 | 2010-11-17 | Schering Corp | Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras |
| AR076126A1 (es) | 2009-03-18 | 2011-05-18 | Schering Corp | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa |
| SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
| SI2429995T1 (sl) | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
| CA2769263C (en) | 2009-07-31 | 2017-03-07 | Global Alliance For Tb Drug Development | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| LT2755963T (lt) | 2011-09-15 | 2020-01-27 | F. Hoffmann-La Roche Ag | Nauji dihidrochinolin-2-ono dariniai |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| SG11201402199QA (en) | 2011-11-30 | 2014-09-26 | Hoffmann La Roche | New bicyclic dihydroisoquinoline-1-one derivatives |
| SI2838883T1 (en) | 2012-04-17 | 2018-02-28 | F. Hoffmann-La Roche Ag | New derivatives of phenyl-tetrahydroisoquinoline |
| AU2013313884B2 (en) | 2012-09-04 | 2016-10-20 | Samsung Electronics Co., Ltd. | Adaptating a number of aggregation levels for control channel elements |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| US8912341B2 (en) | 2013-01-16 | 2014-12-16 | Northwestern University | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones |
| EP2958562B1 (en) | 2013-02-22 | 2025-09-10 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| WO2014168861A2 (en) | 2013-04-08 | 2014-10-16 | Cowans Kenneth W | Air supply concepts to improve efficiency of vcrc engines |
| PT2986304T (pt) | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
| US9181272B2 (en) | 2013-04-30 | 2015-11-10 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| CA2915788A1 (en) | 2013-10-17 | 2015-04-23 | F. Hoffmann-La Roche Ag | New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors |
| AU2015204210B2 (en) | 2014-01-06 | 2019-07-18 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| EP3172212B1 (en) | 2014-07-24 | 2018-06-13 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
| TR201907755T4 (tr) | 2014-10-15 | 2019-06-21 | Boehringer Ingelheim Int | Aldosteron sentaz inhibitörleri. |
| RU2675622C1 (ru) | 2015-01-29 | 2018-12-21 | Медшайн Дискавери Инк. | Производное нитроимидазола против туберкулеза легких |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| MA46742A (fr) | 2016-11-10 | 2019-09-18 | Boehringer Ingelheim Int | Composition pharmaceutique, méthodes de traitement et leurs utilisations |
| CN109053637B (zh) | 2018-08-14 | 2021-03-16 | 杭州泽旺生物科技有限公司 | 尺蠖类性信息素及其中间体的合成方法 |
-
2022
- 2022-12-13 KR KR1020247023466A patent/KR20240122521A/ko active Pending
- 2022-12-13 MX MX2024007335A patent/MX2024007335A/es unknown
- 2022-12-13 CN CN202280082162.7A patent/CN118401241A/zh active Pending
- 2022-12-13 JP JP2024534762A patent/JP2025500826A/ja active Pending
- 2022-12-13 AR ARP220103413A patent/AR127948A1/es not_active Application Discontinuation
- 2022-12-13 US US18/079,904 patent/US12263157B2/en active Active
- 2022-12-13 TW TW111147688A patent/TW202339719A/zh unknown
- 2022-12-13 WO PCT/US2022/052631 patent/WO2023114170A1/en not_active Ceased
- 2022-12-13 CA CA3236890A patent/CA3236890A1/en active Pending
- 2022-12-13 EP EP22850783.6A patent/EP4447961A1/en active Pending
- 2022-12-13 AU AU2022415313A patent/AU2022415313A1/en active Pending
-
2024
- 2024-05-16 CL CL2024001470A patent/CL2024001470A1/es unknown
- 2024-10-29 US US18/930,470 patent/US20250049763A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12263157B2 (en) | 2025-04-01 |
| AU2022415313A1 (en) | 2024-05-02 |
| MX2024007335A (es) | 2024-06-26 |
| EP4447961A1 (en) | 2024-10-23 |
| US20230181538A1 (en) | 2023-06-15 |
| TW202339719A (zh) | 2023-10-16 |
| JP2025500826A (ja) | 2025-01-15 |
| WO2023114170A1 (en) | 2023-06-22 |
| CL2024001470A1 (es) | 2024-09-13 |
| US20250049763A1 (en) | 2025-02-13 |
| KR20240122521A (ko) | 2024-08-12 |
| CN118401241A (zh) | 2024-07-26 |
| CA3236890A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127948A1 (es) | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica | |
| AR125414A2 (es) | INHIBIDORES DE INTEGRINA avb6 | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| US20100048900A1 (en) | Agent for treatment of vascular leaks | |
| BR112017012755A2 (pt) | compostos de heteroarila de anel fundido e seu uso como inibidores de trk | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| AR081261A1 (es) | Metodos para tratar afecciones virales | |
| AR067326A1 (es) | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| BR112015027114A8 (pt) | compostos inibidores seletivos de histona desacetilase, sua composição farmacêutica e seu uso | |
| RU2017108862A (ru) | Лечение патологических состояний суставов | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| AR117640A1 (es) | Compuestos de 2,6-diaminopiridina como inhibidores de khk | |
| HRP20110713T1 (hr) | Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830 | |
| BR112021018254A8 (pt) | Derivados de nicorandil | |
| AR120173A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| AR130094A1 (es) | Inhibidores de inflamasoma nlrp3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |